These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38588523)

  • 21. Existing and emerging treatments for idiopathic pulmonary fibrosis.
    Kolilekas L; Papiris S; Bouros D
    Expert Rev Respir Med; 2019 Mar; 13(3):229-239. PubMed ID: 30632421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN
    Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat.
    Maher TM; Strek ME
    Respir Res; 2019 Sep; 20(1):205. PubMed ID: 31492155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    Xaubet A; Serrano-Mollar A; Ancochea J
    Expert Opin Pharmacother; 2014 Feb; 15(2):275-81. PubMed ID: 24308635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experimental autotaxin inhibitors for the treatment of idiopathic pulmonary fibrosis.
    Simonetti J; Ficili M; Sgalla G; Richeldi L
    Expert Opin Investig Drugs; 2024 Feb; 33(2):133-143. PubMed ID: 38299617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging therapeutic targets for idiopathic pulmonary fibrosis: preclinical progress and therapeutic implications.
    Yanagihara T; Scallan C; Ask K; Kolb MRJ
    Expert Opin Ther Targets; 2021 Nov; 25(11):939-948. PubMed ID: 34784834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
    Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
    Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging therapeutic interventions for idiopathic pulmonary fibrosis.
    Chakraborty S; Chopra P; Ambi SV; Dastidar SG; Ray A
    Expert Opin Investig Drugs; 2014 Jul; 23(7):893-910. PubMed ID: 24766571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries.
    Maher TM; Molina-Molina M; Russell AM; Bonella F; Jouneau S; Ripamonti E; Axmann J; Vancheri C
    BMC Pulm Med; 2017 Sep; 17(1):124. PubMed ID: 28915874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in the treatment of idiopathic pulmonary fibrosis.
    Sergew A; Brown KK
    Expert Opin Emerg Drugs; 2015; 20(4):537-52. PubMed ID: 26629731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis.
    Collins BF; Raghu G
    Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31578210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The earlier, the better: Impact of early diagnosis on clinical outcome in idiopathic pulmonary fibrosis.
    Aiello M; Bertorelli G; Bocchino M; Chetta A; Fiore-Donati A; Fois A; Marinari S; Oggionni T; Polla B; Rosi E; Stanziola A; Varone F; Sanduzzi A
    Pulm Pharmacol Ther; 2017 Jun; 44():7-15. PubMed ID: 28257817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Using forced vital capacity (FVC) in the clinic to monitor patients with idiopathic pulmonary fibrosis (IPF): pros and cons.
    Nathan SD; Wanger J; Zibrak JD; Wencel ML; Burg C; Stauffer JL
    Expert Rev Respir Med; 2021 Feb; 15(2):175-181. PubMed ID: 32985286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic targets in idiopathic pulmonary fibrosis.
    Kolb M; Bonella F; Wollin L
    Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial.
    Podolanczuk AJ; Kim JS; Cooper CB; Lasky JA; Murray S; Oldham JM; Raghu G; Flaherty KR; Spino C; Noth I; Martinez FJ;
    BMC Pulm Med; 2022 Dec; 22(1):475. PubMed ID: 36514019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.
    Ahluwalia N; Shea BS; Tager AM
    Am J Respir Crit Care Med; 2014 Oct; 190(8):867-78. PubMed ID: 25090037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update.
    Wongkarnjana A; Yanagihara T; Kolb MR
    Expert Rev Respir Med; 2019 Dec; 13(12):1139-1146. PubMed ID: 31564185
    [No Abstract]   [Full Text] [Related]  

  • 38. Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis.
    Bonella F; Spagnolo P; Ryerson C
    Drugs; 2023 Nov; 83(17):1581-1593. PubMed ID: 37882943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone.
    Ikeda K; Shiratori M; Chiba H; Nishikiori H; Yokoo K; Saito A; Hasegawa Y; Kuronuma K; Otsuka M; Yamada G; Takahashi H
    Respir Med; 2017 Oct; 131():184-191. PubMed ID: 28947028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis.
    Nambiar AM; Anzueto AR; Peters JI
    PLoS One; 2017; 12(4):e0176312. PubMed ID: 28441449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.